Pradeep Tyagi1, Saundra S Motley2, Tatsuki Koyama3, Mahendra Kashyap1, Jeffrey Gingrich1, Naoki Yoshimura1, Jay H Fowke2,4. 1. Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
PURPOSE: Benign prostatic hyperplasia (BPH) is strongly associated with obesity and prostatic tissue inflammation, but the molecular underpinning of this relationship is not known. Here, we examined the association between urine levels of chemokines/adipokines with histological markers of prostate inflammation, obesity, and lower urinary tract symptoms LUTS in BPH patients. METHODS: Frozen urine specimens from 207 BPH/LUTS patients enrolled in Nashville Men's Health Study were sent for blinded analysis of 11 analytes, namely sIL-1RA, CXC chemokines (CXCL-1, CXCL-8, CXCL-10), CC chemokines (CCL2, CCL3, CCL5), PDGF-BB, interleukins IL-6, IL-17, and sCD40L using Luminex™ xMAP® technology. After adjusting for age and medication use, the urine levels of analytes were correlated with the scales of obesity, prostate inflammation grade, extent, and markers of lymphocytic infiltration (CD3 and CD20) using linear regression. RESULTS: sIL-1RA levels were significantly raised with higher BMI, waist circumference and waist-hip ratio in BPH patients after correction for multiple testing (P = 0.02). Men with greater overall extent of inflammatory infiltrates and maximal CD3 infiltration were marginally associated with CXCL-10 (P = 0.054) and CCL5 (P = 0.054), respectively. CCL3 in 15 patients with moderate to severe grade inflammation was marginally associated with maximal CD20 infiltration (P = 0.09), whereas CCL3 was undetectable in men with mild prostate tissue inflammation. There was marginal association of sCD40L with AUA-SI scores (P = 0.07). CONCLUSIONS: Strong association of sIL-1RA in urine with greater body size supports it as a major molecular correlate of obesity in the urine of BPH patients. Increased urine levels of CXCL-10, CCL5, and CCL3 were marginally associated with the scores for prostate tissue inflammation and lymphocytic infiltration. Overall, elevated urinary chemokines support that BPH is a metabolic disorder and suggest a molecular link between BPH/LUTS and prostatic inflammation.
PURPOSE:Benign prostatic hyperplasia (BPH) is strongly associated with obesity and prostatic tissue inflammation, but the molecular underpinning of this relationship is not known. Here, we examined the association between urine levels of chemokines/adipokines with histological markers of prostate inflammation, obesity, and lower urinary tract symptoms LUTS in BPH patients. METHODS: Frozen urine specimens from 207 BPH/LUTS patients enrolled in Nashville Men's Health Study were sent for blinded analysis of 11 analytes, namely sIL-1RA, CXC chemokines (CXCL-1, CXCL-8, CXCL-10), CC chemokines (CCL2, CCL3, CCL5), PDGF-BB, interleukins IL-6, IL-17, and sCD40L using Luminex™ xMAP® technology. After adjusting for age and medication use, the urine levels of analytes were correlated with the scales of obesity, prostate inflammation grade, extent, and markers of lymphocytic infiltration (CD3 and CD20) using linear regression. RESULTS:sIL-1RA levels were significantly raised with higher BMI, waist circumference and waist-hip ratio in BPH patients after correction for multiple testing (P = 0.02). Men with greater overall extent of inflammatory infiltrates and maximal CD3 infiltration were marginally associated with CXCL-10 (P = 0.054) and CCL5 (P = 0.054), respectively. CCL3 in 15 patients with moderate to severe grade inflammation was marginally associated with maximal CD20 infiltration (P = 0.09), whereas CCL3 was undetectable in men with mild prostate tissue inflammation. There was marginal association of sCD40L with AUA-SI scores (P = 0.07). CONCLUSIONS: Strong association of sIL-1RA in urine with greater body size supports it as a major molecular correlate of obesity in the urine of BPH patients. Increased urine levels of CXCL-10, CCL5, and CCL3 were marginally associated with the scores for prostate tissue inflammation and lymphocytic infiltration. Overall, elevated urinary chemokines support that BPH is a metabolic disorder and suggest a molecular link between BPH/LUTS and prostatic inflammation.
Authors: Ibrahim Kulac; Berrak Gumuskaya; Charles G Drake; Beverly Gonzalez; Kathryn B Arnold; Phyllis J Goodman; Alan R Kristal; M Scott Lucia; Ian M Thompson; William B Isaacs; Angelo M De Marzo; Elizabeth A Platz Journal: Prostate Date: 2016-06-21 Impact factor: 4.104
Authors: Lisa K Spary; Josephine Salimu; Jason P Webber; Aled Clayton; Malcolm D Mason; Zsuzsanna Tabi Journal: Oncoimmunology Date: 2014-12-13 Impact factor: 8.110
Authors: Helena M Linge; Mattias Collin; Aleksander Giwercman; Johan Malm; Anders Bjartell; Arne Egesten Journal: J Interferon Cytokine Res Date: 2008-03 Impact factor: 2.607
Authors: Georg E Steiner; Ursula Stix; Alessandra Handisurya; Martin Willheim; Andrea Haitel; Franz Reithmayr; Doris Paikl; Rupert C Ecker; Kristian Hrachowitz; Gero Kramer; Chung Lee; Michael Marberger Journal: Lab Invest Date: 2003-08 Impact factor: 5.662
Authors: LaTayia M Aaron-Brooks; Takeshi Sasaki; Renee E Vickman; Lin Wei; Omar E Franco; Yuan Ji; Susan E Crawford; Simon W Hayward Journal: Prostate Date: 2019-04-18 Impact factor: 4.104
Authors: Diandra K Smith; Sarrah L Hasanali; Jiaojiao Wang; Georgios Kallifatidis; Daley S Morera; Andre R Jordan; Martha K Terris; Zachary Klaassen; Roni Bollag; Vinata B Lokeshwar; Bal L Lokeshwar Journal: Prostate Date: 2020-06-16 Impact factor: 4.104
Authors: Maria G Grammatikopoulou; Konstantinos Gkiouras; Stefanos Τ Papageorgiou; Ioannis Myrogiannis; Ioannis Mykoniatis; Theodora Papamitsou; Dimitrios P Bogdanos; Dimitrios G Goulis Journal: Nutrients Date: 2020-09-29 Impact factor: 5.717
Authors: Mohamed Raafat; Amr A Kamel; Alaa H Shehata; Al-Shaimaa F Ahmed; Asmaa M A Bayoumi; Rabab A Moussa; Mohammed A S Abourehab; Mahmoud El-Daly Journal: Pharmaceuticals (Basel) Date: 2022-01-22